Intestinal Research

Fecal microbiota transplantation for induction of remission, maintenance and rescue in patients with corticosteroid-dependent ulcerative colitis: a long-term follow-up real-world cohort study: Avnish Kumar Seth, Priti Jain; Intest Res. 2022;20(2):251-259. Published online February 8, 2022; DOI: https://doi.org/10.5217/ir.2021.00069
Cited By 3; Full text PubReader ePub Crossref - TDM PDF Graphic abstract

Landscape of inflammatory bowel disease in Singapore: Daren Low, Nidhi Swarup, Toshiyuki Okada, Emiko Mizoguchi; Intest Res. 2022;20(3):291-296. Published online January 7, 2022; DOI: https://doi.org/10.5217/ir.2021.00089
Cited By 4; Full text PubReader ePub Crossref - TDM PDF

Artificial intelligence for endoscopy in inflammatory bowel disease: Kento Takenaka, Ami Kawamoto, Ryuichi Okamoto, Mamoru Watanabe, Kazuo Ohtsuka; Intest Res. 2022;20(2):165-170. Published online January 7, 2022; DOI: https://doi.org/10.5217/ir.2021.00079
Cited By 2; Full text PubReader ePub Crossref - TDM PDF

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance: Shiro Nakamura, Teita Asano, Hiroaki Tsuchiya, Kanami Sugimoto, Yuya Imai, Seiji Yokoyama, Yasuo Suzuki; Intest Res. 2022;20(3):329-341. Published online August 4, 2021; DOI: https://doi.org/10.5217/ir.2021.00032
Cited By 2; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease: Seung Hyuk Kim, You Sun Kim, Si Hyeong Lee, Hyun Mi Lee, Won Eui Yoon, Seo Hyun Kim, Hee Jun Myung, Jeong Seop Moon; Intest Res. 2022;20(3):321-328. Published online July 20, 2021; DOI: https://doi.org/10.5217/ir.2021.00022
Cited By 1; Full text PubReader ePub Crossref - TDM PDF

Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study: Ramit Mahajan, Arshdeep Singh, Saurabh Kedia, Kirandeep Kaur, Vandana Midha, Pabitra Sahu, Varun Mehta, Dharmatma Singh, Namita Bansal, Khushdeep Dharni, Sandeep Kaushal, Vineet Ahuja, Ajit Sood; Intest Res. 2022;20(1):64-71. Published online February 3, 2021; DOI: https://doi.org/10.5217/ir.2020.00100
Cited By 7; Full text PubReader ePub Crossref - TDM PDF

Inflammatory Bowel Diseases
Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy: Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, Kana Onishi, Takeshi Takasago, Masaki Wakai, Toshikatsu Naito, Kensuke Sasaki, Shigehiro Doi, Takao Masaki, Kazuaki Chayama; Intest Res. 2021;19(4):430-437. Published online November 9, 2020; DOI: https://doi.org/10.5217/ir.2020.00067
Cited By 1; Full text PubReader ePub Crossref - TDM PDF Graphic abstract

Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment: Shintaro Akiyama, Victoria Rai, David T. Rubin; Intest Res. 2021;19(1):1-11. Published online November 5, 2020; DOI: https://doi.org/10.5217/ir.2020.00047
Cited By 13; Full text PubReader ePub Crossref - TDM PDF

Inflammatory Bowel Diseases
Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study: Choon Jin Ooi, Ida Normiha Hilmi, Hyo-Jong Kim, Umesh Jalihal, Deng-Chyang Wu, Dirk Demuth, Dirk Lindner, Shashi Adsul; Intest Res. 2021;19(1):71-82. Published online September 4, 2020; DOI: https://doi.org/10.5217/ir.2019.09159
Cited By 16; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?: Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis; Intest Res. 2021;19(4):461-467. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00042
Cited By 4; Full text PubReader ePub Crossref - TDM PDF

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis: Shin Ju Oh, Ga Young Shin, Hosim Soh, Jae Gon Lee, Jong Pil Im, Chang Soo Eun, Kang-Moon Lee, Dong Il Park, Dong Soo Han, Hyo Jong Kim, Chang Kyun Lee; Intest Res. 2021;19(3):323-331. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00039
Cited By 19; Full text PubReader ePub Crossref - TDM PDF

Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018: Satimai Aniwan, Julajak Limsrivilai, Supot Pongprasobchai, Nonthalee Pausawasdi, Piyapan Prueksapanich, Natanong Kongtub, Rungsun Rerknimitr; Intest Res. 2021;19(2):186-193. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00028
Cited By 12; Full text PubReader ePub Crossref - TDM PDF

Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry: Ajit Sood, Kirandeep Kaur, Ramit Mahajan, Vandana Midha, Arshdeep Singh, Sarit Sharma, Amarender Singh Puri, Bhabhadev Goswami, Devendra Desai, C. Ganesh Pai, Kiran Peddi, Mathew Philip, Rakesh Kochhar, Sandeep Nijhawan, Shobna Bhatia, N. Sridhara Rao; Intest Res. 2021;19(2):206-216. Published online July 13, 2020; DOI: https://doi.org/10.5217/ir.2019.09169
Cited By 16; Full text PubReader ePub Crossref - TDM PDF Graphic abstract

Inflammatory bowel diseases
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease: Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kirandeep Kaur, Rajeev Khosla, Ajay Kumar, Ramit Mahajan, S. P. Misra, Kiran Peddi, Shivaram Prasad Singh, Arshdeep Singh; Intest Res. 2020;18(4):355-378. Published online July 13, 2020; DOI: https://doi.org/10.5217/ir.2019.09176
Cited By 10; Full text PubReader ePub Crossref - TDM PDF

Inflammatory Bowel Diseases
Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease: Hiroyuki Okamoto, Nathanael L. Dirks, Maria Rosario, Tetsuharu Hori, Toshifumi Hibi; Intest Res. 2021;19(1):95-105. Published online July 10, 2020; DOI: https://doi.org/10.5217/ir.2019.09167
Cited By 11; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Search